Search results for " Drug"

showing 10 items of 3138 documents

Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventing recurrent bacterial cystitis? A multicenter case control…

2015

Abstract Objective Urinary tract infections (UTIs) are common in the female population and, over a lifetime, about half of women have at least one episode of UTI requiring antibiotic therapy. The aim of the current study was to compare two different strategies for preventing recurrent bacterial cystitis: intravesical instillation of hyaluronic acid (HA) plus chondroitin sulfate (CS), and antibiotic prophylaxis with sulfamethoxazole plus trimethoprim. Materials and methods This was a retrospective review of two different cohorts of women affected by recurrent bacterial cystitis. Cases (experimental group) were women who received intravesical instillations of a sterile solution of high concen…

Adultmedicine.medical_specialtyRecurrent bacterial cystitismedicine.drug_classUrinary systemCystitiAntibioticsUrinalysislcsh:Gynecology and obstetricsGastroenterologyantibioticsantibiotics; chondroitin sulfate; cystitis; hyaluronic acidchemistry.chemical_compoundAdjuvants ImmunologicRecurrenceInternal medicineObstetrics and GynaecologyHyaluronic acidCystitismedicineHumansChondroitin sulfateAntibiotic prophylaxisHyaluronic Acidlcsh:RG1-991antibiotics chondroitin sulfate cystitis hyaluronic acidchondroitin sulfateRetrospective StudiesDose-Response Relationship Drugbusiness.industrySulfamethoxazoleChondroitin SulfatesAntibioticObstetrics and GynecologySettore MED/40 - Ginecologia E OstetriciaTrimethoprimSurgeryAdministration IntravesicalInstillation DrugchemistryUrinary Tract InfectionsDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesTaiwanese journal of obstetricsgynecology
researchProduct

Sympathetic nervous activity and the pressor effect of noradrenaline under chronic?-?-adrenoceptor blockade with labetalol in hypertension

1983

In 14 patients with essential hypertension, the influence of the alpha- and beta-adrenoceptor blocking drug labetalol on blood pressure, heart rate, plasma renin, plasma noradrenaline and pressor effect of exogenous noradrenaline was investigated during long-term treatment. During the initial four weeks of treatment, labetalol at a dose of 400 mg/day showed a slight effect only on supine blood pressure, whereas upright blood pressure was already lowered effectively after the second week of treatment (p less than 0.01). An increase in the mean dose to 850 mg/day had an additional blood pressure-lowering effect (p less than 0.001), whereby a preferential decrease of the orthostatic blood pres…

Adultmedicine.medical_specialtySympathetic Nervous SystemSupine positionPostureAlpha (ethology)Blood PressureEssential hypertensionPlasma renin activityPlacebosNorepinephrineInternal medicineReceptors Adrenergic betaReninDrug DiscoveryHeart ratemedicineHumansDrug InteractionsLabetalolLabetalolGenetics (clinical)Plasma noradrenalineDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle AgedReceptors Adrenergic alphamedicine.diseaseReceptors AdrenergicEndocrinologyBlood pressureEthanolaminesChronic DiseaseHypertensionMolecular Medicinebusinesscirculatory and respiratory physiologymedicine.drugKlinische Wochenschrift
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Inn…

2007

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follo…

Adultmedicine.medical_specialtyVincristineAntibodies NeoplasmImmunologyKaplan-Meier EstimateCHOPAntibodies Monoclonal HumanizedBiochemistryGastroenterologyChemoimmunotherapyAntigens CDAntigens NeoplasmMulticenter trialInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMulticenter Studies as TopicAlemtuzumabCyclophosphamideSocieties MedicalAgedGlycoproteinsDose-Response Relationship Drugbusiness.industryPralatrexateAntibodies MonoclonalLymphoma T-Cell PeripheralCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryRegimenCD52 AntigenItalyDoxorubicinVincristineAlemtuzumabPrednisonebusinessProgressive diseasemedicine.drug
researchProduct

Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding …

2009

Abstract Background A dose-finding study was performed as the first step in the clinical development of the new drug, cizolirtine citrate. Objective To assess the efficacy and safety of cizolirtine citrate in overactive bladder with urinary incontinence. Design, setting, and participants Seventy-nine outpatients with clinical overactive bladder and/or urodynamic diagnosis of detrusor overactivity were randomized in a multicentre, 12-wk, double-blind, pilot trial. Interventions Patients received cizolirtine citrate 400mg bid (C400), cizolirtine citrate 200mg bid (C200), or placebo. Measurements Patients recorded efficacy variables in 7- and 14-d bladder diaries: urinary incontinence episodes…

Adultmedicine.medical_specialtyVomitingCalcitonin Gene-Related PeptideUrologyUrinary systemVision DisordersUrologyPilot ProjectsUrinary incontinenceSubstance PPlaceboDizzinesslaw.inventionYoung AdultDouble-Blind MethodRandomized controlled triallawmedicineHumansAdverse effectAgedAged 80 and overUrinary bladderDose-Response Relationship DrugUrinary Bladder Overactivebusiness.industryNauseaMiddle Agedmedicine.diseaseUrodynamicsUrinary Incontinencemedicine.anatomical_structureTolerabilityOveractive bladderPyrazolesFemalemedicine.symptombusinessEuropean Urology
researchProduct

Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission.…

2019

Abstract To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as first-line therapy, in inducing remission in naïve Adult-onset Still's disease (AOSD) patients compared with low dosage of CCSs, after 6 months. To further evaluate the rate of patients maintaining the remission and the rate of CCSs discontinuation, after additional 12 months of follow-up. A retrospective evaluation of patients prospectively followed was designed to compare the rate of clinical remission in naïve AOSD patients treated with high dosages of CCSs (0.8–1 mg/kg/day of prednisone-equivalent) or low dosage of CCSs (0.2–0.3 mg/kg/day of prednisone-equivalent), after 6 months. An add…

Adult-OnsetMalePediatricsAdult-onset Still's diseaseDiseaseAdrenal Cortex Hormonecorticosteroids0302 clinical medicinemonocyclic patternAdrenal Cortex HormonesRetrospective StudieMedicine030212 general & internal medicineProspective StudiesProspective cohort studyRemission InductionDisease ManagementGeneral MedicineMiddle AgedTreatment OutcomeHigh dosage030220 oncology & carcinogenesisFemaleDrugStill's Disease Adult-OnsetResearch ArticleHumanAdultcorticosteroidmedicine.medical_specialtyLow dosageObservational StudyAdult-onset Still's diseaseFollow-Up StudieDose-Response Relationship03 medical and health sciencesremissionAdult-onset Still's disease; corticosteroids; first-line therapy; monocyclic pattern; remission; Adrenal Cortex Hormones; Adult; Disease Management; Dose-Response Relationship Drug; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Retrospective Studies; Still's Disease Adult-Onset; Treatment Outcomefirst-line therapyHumansRetrospective StudiesDose-Response Relationship Drugbusiness.industry6900Retrospective cohort studyStill's DiseaseFirst line treatmentSettore MED/16 - ReumatologiaProspective StudieMethotrexateObservational studybusinessFollow-Up Studies
researchProduct

Multimorbidity and polypharmacy in the elderly: Lessons from REPOSI

2014

none 10 no The dramatic demographic changes that are occurring in the third millennium are modifying the mission of generalist professionals such as primary care physicians and internists. Multiple chronic diseases and the related prescription of multiple medications are becoming typical problems and present many challenges. Unfortunately, the available evidence regarding the efficacy of medications has been generated by clinical trials involving patients completely different from those currently admitted to internal medicine: much younger, affected by a single disease and managed in a highly controlled research environment. Because only registries can provide information on drug effectiven…

Adverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged; 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies; Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineMalemedicine.medical_specialtyAgingmedia_common.quotation_subjectDrug prescriptionMEDLINEAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineDiseaseComorbidityAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; PolypharmacyelderlyAdverse drug effectsPromotion (rank)MedicalmedicineAdverse drug effect80 and overInternal MedicineHumansRegistriesMedical prescriptionmedia_commonAgedGeriatricsPolypharmacyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Emergency Medicine; Internal MedicineMultimorbidity Polypharmacy Aging Drug prescription Multidimensional evaluation Adverse drug effectsMultidimensional evaluationbusiness.industrySettore MED/09 - MEDICINA INTERNAMultimorbiditymedicine.diseaseComorbidityelderly multimorbidity polypharmacyClinical trialItalyGeriatricsFamily medicinePolypharmacyEmergency MedicineFemaleMedical emergencyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Internal Medicine; Emergency MedicinebusinessSocietiesmultimorbidity; polypharmacy; aging; drug prescription; multidimensional evaluation; adverse drug effectsMultimorbidity; Polypharmacy; Aging; Drug prescription; Multidimensional evaluation
researchProduct

Fatal multi-organ failure following anaphylactic shock induced by ceftriaxone

2014

In the latest years, based on the wide use of cephalosporins for antibiotic therapy, a large interest focused on the identification of causal relationship of adverse reactions after their prescription. We report a case of fatal anaphylactic shock following the administration of ceftriaxone in a woman who had tolerated the previous exposure to the drug. This case adds a contribution to the few cases reported in literature to further suggest the possibility of severe anaphylaxis after the administration of ceftriaxone even in patients without any previous reaction to this drug.

Adverse drug reaction; Anaphylaxis; Ceftriaxone; Cephalosporins; Multi-organ failure; Shock; Immunology and AllergySettore MED/43 - Medicina LegaleAnaphylaxiCeftriaxoneCephalosporinAdverse drug reactionImmunology and AllergyShockMulti-organ failureAnaphylaxisCephalosporins
researchProduct

Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment

2011

In a number of adverse drug reactions leading to hepatotoxicity, drug metabolism is thought to be involved by the generation of reactive metabolites from non-toxic drugs. The use of hepatoma cell lines, such as HepG2 cell line, for the evaluation of drug-induced hepatotoxicity is hampered by their low cytochrome P450 expression which makes impossible the study of the toxicity produced by bioactivable compounds. Genetically manipulated cells constitute promising tools for hepatotoxicity applications. HepG2 cells were simultaneously transfected with recombinant adenoviruses encoding CYP1A2, CYP2C9 and CYP3A4 to confer them drug-metabolic competence. Upgraded cells (Adv-HepG2) were highly able…

Aflatoxin B1Cell SurvivalGenetic VectorsPharmacologyTransfectionToxicologyModels BiologicalCitric AcidCalcium in biologyAdenoviridaeCytochrome P-450 CYP1A2RotenoneCytochrome P-450 CYP3AHumansViability assayCytochrome P-450 CYP2C9Membrane Potential MitochondrialCYP3A4biologyChemistryCYP1A2Cytochrome P450Hep G2 CellsGeneral MedicineTransfectionBiochemistryHigh-content screeningbiology.proteinCalciumAryl Hydrocarbon HydroxylasesChemical and Drug Induced Liver InjuryDrug metabolismToxicology in Vitro
researchProduct

Effect of allyl isothiocyanate on transcriptional profile, aflatoxin synthesis, and Aspergillus flavus growth.

2020

Abstract The goals of this study were to determine the efficacy of allyl isothiocyanate (AITC) against the growth of A. flavus and Aflatoxin B1 (AFB1) production as well as to evaluate changes in the transcriptome profile when colonizing maize. A. flavus was inoculated in potato dextrose agar (PDA), the plates were placed inside glass jars and the mycelial growth (MG) was monitored for 7 d. Likewise, maize grains were contaminated with A. flavus in glass jars of 1 L and treated with 0.125, 0.25, 0.5, 1 and 5 µL of AITC. The moisture content (MC) of grains was 15 and 21%. After 7 days of storage, the MG was significantly reduced in doses higher than 0.125 µL/L of AITC. All doses of AITC redu…

AflatoxinAntifungal Agents030309 nutrition & dieteticsAspergillus flavusTranscriptome03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyAflatoxinsIsothiocyanatesGene Expression Regulation FungalFood scienceMyceliumAflatoxin synthesis0303 health sciencesbiologyDose-Response Relationship DrugChemistryInoculationfood and beverages04 agricultural and veterinary sciencesbiology.organism_classificationAllyl isothiocyanate040401 food scienceFood PreservativesPotato dextrose agarTranscriptomeFood ScienceAspergillus flavusFood research international (Ottawa, Ont.)
researchProduct